Skip to main content

Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Celldex (CLDX)

Tipranks - Thu Feb 26, 9:56AM CST

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ionis Pharmaceuticals (IONSResearch Report), Celldex (CLDXResearch Report) and Pfizer (PFEResearch Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

Ionis Pharmaceuticals (IONS)

William Blair analyst Myles Minter maintained a Buy rating on Ionis Pharmaceuticals today. The company’s shares closed last Wednesday at $81.73.

According to TipRanks.com, Minter is a 5-star analyst with an average return of 28.2% and a 58.8% success rate. Minter covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, Neumora Therapeutics, Inc., and Entrada Therapeutics Inc. ;'>

Currently, the analyst consensus on Ionis Pharmaceuticals is a Strong Buy with an average price target of $97.22.

See the top stocks recommended by analysts >>

Celldex (CLDX)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Celldex today and set a price target of $42.00. The company’s shares closed last Wednesday at $29.17.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 12.0% and a 46.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Adlai Nortye Ltd. Sponsored ADR, NewAmsterdam Pharma Company, and XOMA Royalty Corporation. ;'>

Celldex has an analyst consensus of Moderate Buy, with a price target consensus of $44.00.

Pfizer (PFE)

In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Pfizer. The company’s shares closed last Wednesday at $26.75.

According to TipRanks.com, Raffat is a 4-star analyst with an average return of 6.2% and a 49.2% success rate. Raffat covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Eli Lilly & Co, and Royalty Pharma. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Pfizer with a $28.66 average price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.